SK279641B6 - Stabilizovaný farmaceutický prípravok obsahujúci r - Google Patents

Stabilizovaný farmaceutický prípravok obsahujúci r Download PDF

Info

Publication number
SK279641B6
SK279641B6 SK754-94A SK75494A SK279641B6 SK 279641 B6 SK279641 B6 SK 279641B6 SK 75494 A SK75494 A SK 75494A SK 279641 B6 SK279641 B6 SK 279641B6
Authority
SK
Slovakia
Prior art keywords
histidine
growth hormone
hgh
crystals
pharmaceutical composition
Prior art date
Application number
SK754-94A
Other languages
English (en)
Slovak (sk)
Other versions
SK75494A3 (en
Inventor
Hans H. Sorensen
Lars Skriver
Annie R. Hoelgaard
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK204691A external-priority patent/DK204691D0/da
Priority claimed from DK136492A external-priority patent/DK136492D0/da
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of SK75494A3 publication Critical patent/SK75494A3/sk
Publication of SK279641B6 publication Critical patent/SK279641B6/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK754-94A 1991-12-20 1992-12-16 Stabilizovaný farmaceutický prípravok obsahujúci r SK279641B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK204691A DK204691D0 (da) 1991-12-20 1991-12-20 Hidtil ukendt farmaceutisk praeparat
DK136492A DK136492D0 (da) 1992-11-10 1992-11-10 A pharmaceutical formulation
PCT/DK1992/000379 WO1993012812A1 (fr) 1991-12-20 1992-12-16 Formulation pharmaceutique stabilisee comportant une somatotrophine et de l'histidine

Publications (2)

Publication Number Publication Date
SK75494A3 SK75494A3 (en) 1995-03-08
SK279641B6 true SK279641B6 (sk) 1999-01-11

Family

ID=26065653

Family Applications (1)

Application Number Title Priority Date Filing Date
SK754-94A SK279641B6 (sk) 1991-12-20 1992-12-16 Stabilizovaný farmaceutický prípravok obsahujúci r

Country Status (24)

Country Link
EP (2) EP1197222B1 (fr)
JP (2) JP2950617B2 (fr)
KR (1) KR100266502B1 (fr)
AT (2) ATE227583T1 (fr)
AU (1) AU667503B2 (fr)
BG (1) BG63075B1 (fr)
CA (1) CA2125855C (fr)
CZ (1) CZ283361B6 (fr)
DE (3) DE69232847T2 (fr)
DK (1) DK0618807T3 (fr)
ES (2) ES2291264T3 (fr)
FI (1) FI115116B (fr)
HU (1) HUT69402A (fr)
IL (1) IL104152A (fr)
MX (1) MX9207374A (fr)
NL (1) NL300126I1 (fr)
NO (1) NO942300L (fr)
NZ (1) NZ246556A (fr)
PT (1) PT618807E (fr)
RO (1) RO111990B1 (fr)
RU (1) RU2122426C1 (fr)
SK (1) SK279641B6 (fr)
UA (1) UA41502C2 (fr)
WO (1) WO1993012812A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
WO1995035116A1 (fr) * 1994-06-17 1995-12-28 Applied Research Systems Compositions pharmaceutiques renfermant l'hch
IL114030A (en) * 1994-06-27 2000-08-13 Hayashibara Biochem Lab Saccharide composition with a lesser reducibility its preparation and compositions containing it
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
EP0805689A1 (fr) * 1995-01-13 1997-11-12 Novo Nordisk A/S Formulation pharmaceutique stabilisee comprenant une hormone de croissance et lys-x
ZA96122B (en) * 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
US6936289B2 (en) 1995-06-07 2005-08-30 Danisco A/S Method of improving the properties of a flour dough, a flour dough improving composition and improved food products
ZA965367B (en) * 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
AU1302499A (en) * 1997-11-12 1999-05-31 Alza Corporation Buffered drug formulations for transdermal electrotransport delivery
EP2311436A1 (fr) * 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Cristaux de protéines stabilisées, formulations renfermant lesdits cristaux et leurs procèdes de fabrication
AU2001238540A1 (en) 2000-02-24 2001-09-03 Monsanto Technology Llc Non-aqueous injectable formulations for extended release of somatotropin
WO2002000261A2 (fr) 2000-06-26 2002-01-03 Monsanto Technology Llc Formulations contenant des tensio-actifs non aqueux permettant une liberation prolongee de somatropine
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
MXPA03001092A (es) 2000-08-07 2003-09-25 Nektar Therapeutics Al Corp Polvos de proteina de haz de 4 helices secados por rocio, inhalables, que tienen agregacion minimizada.
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
CN100591212C (zh) 2001-05-18 2010-02-24 丹尼斯科有限公司 改善生面团和面包质量的方法
EP1581251B1 (fr) 2002-12-31 2016-03-16 Althea Technologies, Inc. Cristaux d'hormone de croissance humaine et procédés de préparation correspondants
NZ554885A (en) * 2002-12-31 2009-07-31 Altus Pharmaceuticals Inc Complexes of hgh crystals and protamine polymers
BRPI0413276B8 (pt) 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
MX2007000627A (es) 2004-07-16 2007-06-25 Danisco Metodo enzimatico de desgomado de aceite.
DK1827483T3 (da) * 2004-12-15 2014-10-06 Swedish Orphan Biovitrum Ab Publ Terapeutiske formuleringer af keratinocyt-vækstfaktor
US7816320B2 (en) * 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
EP1928906A2 (fr) * 2005-08-30 2008-06-11 Novo Nordisk Health Care AG Formulations liquides d'hormone de croissance pegylee
WO2007033427A1 (fr) * 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation de peptides comprenant des acides aminés basiques
PL1969004T3 (pl) 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
EP2040757A2 (fr) 2006-07-07 2009-04-01 Novo Nordisk Health Care AG Nouveaux conjugués de protéines et leurs procédés de préparation
EP2486916B1 (fr) * 2006-12-18 2015-04-01 Ajinomoto Althea, Inc. Formules d'hormone à croissance humaine
WO2008152106A1 (fr) 2007-06-13 2008-12-18 Novo Nordisk A/S Formulation pharmaceutique contenant un dérivé d'insuline
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
JP5658167B2 (ja) * 2008-12-16 2015-01-21 ジェンザイム・コーポレーション オリゴ糖−タンパク複合体
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
AU2010341518B2 (en) 2009-12-21 2014-01-09 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
BR112013008103B1 (pt) * 2010-09-21 2021-01-26 Ferring B.V. processo para a produção do hormônio de crescimento humano (hgh) e método para reduzir a quantidade de formas poliméricas do hgh durante um processo para a produção de hgh
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
JP6162606B2 (ja) 2011-01-14 2017-07-12 レッドウッド バイオサイエンス, インコーポレイテッド アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法
EP2854764B1 (fr) 2012-06-05 2018-12-12 Neuroderm Ltd Compositions comprenant de l'apomorphine et des acides organiques, et leurs utilisations
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014177623A1 (fr) 2013-04-30 2014-11-06 Novo Nordisk A/S Schéma d'administration d'un nouveau type
US11559580B1 (en) * 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
KR102429287B1 (ko) * 2015-12-10 2022-08-05 가부시끼가이샤 메니콘 펩티드 조성물
EP3448885A4 (fr) 2016-04-26 2020-01-08 R.P. Scherer Technologies, LLC Conjugués d'anticorps et méthodes de fabrication et d'utilisation de ceux-ci
US20210188941A1 (en) * 2018-05-25 2021-06-24 Dr. Reddy's Laboratories Limited Stable fusion protein formulation
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2022197963A1 (fr) * 2021-03-19 2022-09-22 Pfizer Inc. Compositions d'hormone de croissance à action prolongée

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
EP0374120A3 (fr) * 1988-12-13 1991-07-31 Monsanto Company Composition pour la libération contrôlée des polypeptides
DK168790D0 (fr) * 1990-07-13 1990-07-13 Novo Nordisk As

Also Published As

Publication number Publication date
MX9207374A (es) 1993-07-01
HUT69402A (en) 1995-09-28
FI942906A0 (fi) 1994-06-17
EP0618807A1 (fr) 1994-10-12
ATE227583T1 (de) 2002-11-15
JPH11315031A (ja) 1999-11-16
DE69232847T2 (de) 2003-09-11
DE69233704T2 (de) 2008-05-21
WO1993012812A1 (fr) 1993-07-08
AU3344693A (en) 1993-07-28
KR100266502B1 (ko) 2000-09-15
EP1197222B1 (fr) 2007-08-01
BG63075B1 (bg) 2001-03-30
EP1197222A3 (fr) 2004-02-04
NO942300D0 (no) 1994-06-17
CZ283361B6 (cs) 1998-03-18
DE10399015I2 (de) 2008-08-07
DE10399015I1 (de) 2012-05-03
CA2125855A1 (fr) 1993-07-08
HU9401832D0 (en) 1994-09-28
CA2125855C (fr) 2008-05-13
SK75494A3 (en) 1995-03-08
RO111990B1 (ro) 1997-04-30
JPH07502516A (ja) 1995-03-16
DE69232847D1 (de) 2002-12-19
NO942300L (no) 1994-08-19
ES2185625T3 (es) 2003-05-01
IL104152A0 (en) 1993-05-13
BG98806A (bg) 1995-02-28
FI115116B (fi) 2005-03-15
NL300126I1 (nl) 2003-07-01
UA41502C2 (uk) 2001-09-17
FI942906A (fi) 1994-06-17
PT618807E (pt) 2003-03-31
RU2122426C1 (ru) 1998-11-27
NZ246556A (en) 1996-03-26
DE69233704D1 (de) 2007-09-13
CZ150794A3 (en) 1995-01-18
DK0618807T3 (da) 2003-03-03
AU667503B2 (en) 1996-03-28
IL104152A (en) 1998-06-15
EP0618807B1 (fr) 2002-11-13
EP1197222A2 (fr) 2002-04-17
ES2291264T3 (es) 2008-03-01
RU94045932A (ru) 1997-04-20
ATE368472T1 (de) 2007-08-15
JP2950617B2 (ja) 1999-09-20

Similar Documents

Publication Publication Date Title
SK279641B6 (sk) Stabilizovaný farmaceutický prípravok obsahujúci r
US5849700A (en) Pharmaceutical formulation
US5849704A (en) Pharmaceutical formulation
CA2252535C (fr) Formulation pharmaceutique contenant une hormone de croissance, un acide amine et un detergent non ionique
US5851992A (en) Treatment of growth hormone deficiency
CZ9498A3 (cs) Farmaceutický přípravek obsahující růstový hormon předem ošetřený zinkem a popřípadě lysinem nebo vápenatými ionty
US8841252B2 (en) Pharmaceutical formulation
US5654278A (en) Composition and method comprising growth hormone and leucine
JP4064453B2 (ja) 成長ホルモンおよびバリンを含んでなる医薬製剤
EP0785797B1 (fr) Formulation pharmaceutique comportant une hormone de croissance et de la leucine
US6022858A (en) Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5552385A (en) Pharmaceutical formulation
CZ6198A3 (cs) Stabilizovaný farmaceutický přípravek obsahující růstový hormon a peptid
PL171356B1 (pl) Sposób wytwarzania kryształów hormonu wzrostu lub pochodnych hormonu wzrostu i histydyny lub pochodnej histydyny
MXPA98008786A (en) A pharmaceutical formulation containing a growth hormone, an amino acid and a non-ion detergent
MXPA98000358A (en) Stabilized pharmaceutical formulation comprising a pretracted growth hormone with zincy optionally lysine or ions cal

Legal Events

Date Code Title Description
PC4A Assignment and transfer of rights

Owner name: NOVO NORDISK HEALTH CARE AG, ZURICH, CH

Free format text: FORMER OWNER: NOVO NORDISK A/S, BAGSVAERD, DK

Effective date: 20110804

MK4A Patent expired

Expiry date: 20121216